Human papillomavirus (HPV) infection causes virtually all cases of cervical cancer, the
second most common cause of death from cancer among women worldwide. This Review …

Highlights•Current prophylactic vaccines protect only against infection with high risk types
HPV16 and 18.•Several new platform technologies are being applied to the development of …

Cervical and other anogenital cancers are initiated by infection with one of a small group of
human papillomaviruses (HPV). Virus-like particle-based vaccines have recently been …

Cancer of the uterine cervix is the second largest cause of cancer deaths in women, and its
toll is greatest in populations that lack screening programmes to detect precursor lesions …

An investigational monovalent human papillomavirus (HPV) 16 virus-like particle vaccine
has been shown to prevent persistent infection and cervical disease related to HPV 16 and …

Human papillomavirus (HPV) is a necessary cause of cervical cancer. In addition, on the
basis of the fulfillment of a combination of viral as well as epidemiological criteria, it is …

The majority of human papillomavirus (HPV) belong to the genus alpha-papillomavirus,
which can be further subdivided into species and then strains. Approximately 200 strains of …

Vaccines are available against human papillomavirus (HPV), the causal agent of cervical
and other cancers. Efficacy data from the HPV-16/18 AS04-adjuvanted vaccine clinical trial …

Introduction: Identification of human papillomavirus (HPV) as the etiologic factor of cervical,
anogenital, and a subset of head and neck cancers has stimulated the development of …

Vaccines for preventing human papillomavirus (HPV) infection are far along in clinical
development and testing and hold great promise for reducing HPV infections and HPV …